Gong Junling, Liu Xing
Department of Obstetrics and Gynecology, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China.
Department of Infectious Disease, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China.
Exp Ther Med. 2018 Jan;15(1):919-923. doi: 10.3892/etm.2017.5474. Epub 2017 Nov 9.
The effect of hepatitis B immune globulin (HBIG) combined with hepatitis B vaccine on blocking hepatitis B virus (HBV) transmission between mother and infant and its effect on immune cells were studied. Ninety newborn infants confirmed to be HBV surface antigen (HBsAg)-positive were divided equally into three groups. Group A newborns received the hepatitis B vaccine at 0, 1 and 6 months after birth (10 µg/time). Group B newborns received an intramuscular injection of 100 IU HBIG 2 h after birth before the same treatment as group A. Mothers of group C newborns received three gluteus maxinus injections of 200 IU HBIG. The newborns in group C got the same treatment as group B. The blocking effect of HBV transmission between mother and infant was evaluated, and cell immune function was assessed. There were significant differences in comparison of blocking success rates between group A and B, and between group A and C as well (p<0.05). At the end of 12 months follow-up, the CD4 level and CD4/CD8 ratio in group C were higher thanthose in group A and B (p<0.05). In addition, the level of CD8 T lymphocyte in group C was lower than those in group A and B (p<0.05). In comparison of levels of CD4T lymphocyte at the end of 12 months follow-up and 24 h after birth, the differences were significant (p<0.05) in bothgroup B and C. The differences of IFN-γ levels betweengroups B/C and group A were significant (p<0.05). Forthose newborn infants born to mothers who were positivefor both HBsAg and HBeAg, HBIG intervention formothers during late pregnancy, together with combinedtreatment of HBIG and hepatitis B vaccine for infants, gavebetter blocking result of HBV transmission.
研究了乙肝免疫球蛋白（HBIG）联合乙肝疫苗对母婴间乙肝病毒（HBV）传播的阻断作用及其对免疫细胞的影响。将90例确诊为乙肝表面抗原（HBsAg）阳性的新生儿平均分为三组。A组新生儿在出生后0、1和6个月接种乙肝疫苗（10μg/次）。B组新生儿在出生后2小时肌肉注射100IU HBIG，然后接受与A组相同的治疗。C组新生儿的母亲在妊娠晚期臀部肌肉注射3次200IU HBIG。C组新生儿接受与B组相同的治疗。评估母婴间HBV传播的阻断效果，并评估细胞免疫功能。A组与B组、A组与C组的阻断成功率比较差异有统计学意义（p<0.05）。随访12个月结束时，C组的CD4水平和CD4/CD8比值高于A组和B组（p<0.05）。此外，C组的CD8 T淋巴细胞水平低于A组和B组（p<0.05）。比较随访12个月结束时和出生后24小时的CD4T淋巴细胞水平，B组和C组差异均有统计学意义（p<0.05）。B/C组与A组的IFN-γ水平差异有统计学意义（p<0.05）。对于母亲HBsAg和HBeAg均阳性的新生儿，母亲在妊娠晚期进行HBIG干预，同时对婴儿联合使用HBIG和乙肝疫苗进行治疗，对HBV传播的阻断效果更好。
